The University of Arizona

PCH Announces Molecular Medicine Institute with UA College of Medicine-Phoenix

By University Communications, December 4, 2012

The state-of-the-art medical research institute will bring new hope to young patients facing life-threatening diseases with sophisticated genomic analysis and real-time access to drugs.

UA College of Medicine-Phoenix
UA College of Medicine-Phoenix
Dr. Robert Arceci, Dr. Daniel Von Hoff and Dr. Timothy Triche, standing left to right, at the announcement of the new Ronald A. Matricaria Institute of Molecular Medicine at Phoenix Children’s Hospital in partnership with the UA College of Medicine-Phoenix and TGen.
Dr. Robert Arceci, Dr. Daniel Von Hoff and Dr. Timothy Triche, standing left to right, at the announcement of the new Ronald A. Matricaria Institute of Molecular Medicine at Phoenix Children’s Hospital in partnership with the UA College of Medicine-Phoenix and TGen.

PHOENIX – Phoenix Children’s Hospital has announced the creation of the Ronald A. Matricaria Institute of Molecular Medicine with the University of Arizona College of Medicine-Phoenix and the Translational Genomics Research Institute, with the goal to unlock genetic codes and develop drug therapies in real time to improve the outcome for thousands of young patients.

“Our goal is to bring genomics research to the forefront of pediatrics,” said Robert L. Meyer, Phoenix Children’s president and CEO. “Research and development of novel treatments for pediatric diseases has fallen short over past decades.”

According to the National Heart, Lung and Blood Institute, 70 percent of all medications prescribed to children have been tested only in adults. Clinical studies in children lead to a better understanding of the specific differences between children and adults, thus leading to the development of safer, more effective and age-appropriate treatments.

“We also must address a fundamental flaw in traditional and personalized medicine – diagnosis and treatment of a disease based on clinical instead of genomic information,” Meyer said.

Molecular, or personalized, medicine uses genetic information to determine the right treatment for the right patient at the right time. By studying a patient’s genetic makeup, researchers can identify the individual’s susceptibility to disease, predict their response to a particular drug and match the patient with a specific therapy.

The team will focus on pediatric cancers in phase one and expand to other pediatric diseases over time.

Two distinguished scientists are joining Phoenix Children's and were named the institute's co-directors: Dr. Timothy Triche, a professor of pathology, cancer biology and pediatrics from the Keck School of Medicine at the University of Southern California and director of the Center for Personalized Medicine at Children's Hospital Los Angeles, and Dr. Robert Arceci, King Fahd Director of Pediatric Oncology at the Johns Hopkins School of Medicine.

A critical component to this venture is Phoenix Children’s collaborative relationships with leading bioscience institutions. The UA College of Medicine-Phoenix brings academic and research programs, as well as academic credentials necessary to recruit and develop a research program. The college used a $1.25 million gift from the Virginia G. Piper Charitable Trust to help secure the two endowed chairs.

“This institute is a critical piece in the development of our campus and the emerging academic medical center in Phoenix,” said Dr. Stuart D. Flynn, dean of the College of Medicine-Phoenix. “This program will catalyze Phoenix Children’s Hospital and our region to become national contributors and leaders in molecular medicine.”

The Translational Genomics Research Institute, or TGen, contributes deep expertise in genomics and bioinformatics and sophisticated laboratory space. Joining the leadership team in a collaborative role is Dr. Daniel Von Hoff, physician in chief, senior investigator and director of translational research for TGen, who will leverage his experience in clinical trials for adults to advance therapy development in children.

“A challenge with existing molecular medicine programs is the amount of time that it takes to develop a new drug or treatment,” Meyer said. “Our collaboration with TGen and the University of Arizona opens the doors to making a portfolio of drugs and compounds available immediately.”

Cancer is the leading cause of death from disease among children in the United States, and the need for pediatric cancer therapies is especially acute. “Half of all childhood cancer patients will relapse, yet virtually no new therapy has been introduced in the past two decades,” said Von Hoff, a former director of The University of Arizona Cancer Center.

A founding gift by Ronald A. Matricaria provided the initial investment to establish the institute. Matricaria is a member of the Phoenix Children’s Hospital board of directors and former chairman/CEO of St. Jude Medical, Inc. Additional funding for the $50 million venture will come from philanthropic contributions and grant revenue. Initially, the institute will employ 50 scientists and other staff, contributing to Phoenix’s growing biomedical corridor.

“I’m thrilled to be part of this groundbreaking venture,” Matricaria said. “Based on my knowledge of the institute and many years of working in the medical field, I’m confident that we can chart a new course for addressing the unique needs of children with cancer and other life-threatening diseases.”